# OnCo record nct05814354 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05814354/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05814354", "NCT05814354" ;
  schema:name "SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial"@en ;
  schema:description "A phase 3 trial of Trastuzumab rezetecan, Capecitabine, Eribulin, Gemcitabine and Paclitaxel / nab-paclitaxel in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05814354/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05814354> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-06-30" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .